Holmberg L, Anderson H
Regional Oncologic Centre, University Hospital, SE-751 85 Uppsala, Sweden.
Lancet. 2004 Feb 7;363(9407):453-5. doi: 10.1016/S0140-6736(04)15493-7.
In the 1990s, two randomised clinical trials started in Scandinavia addressing whether hormone replacement therapy (HRT) is safe for women with previous breast cancer. We report the findings of the safety analysis in HABITS (hormonal replacement therapy after breast cancer--is it safe?), an open randomised clinical trial with allocation to either HRT or best treatment without hormones. The main endpoint was any new breast cancer event. All analyses were done according to intention-to-treat. Until September, 2003, 434 women were randomised; 345 had at least one follow-up report. After a median follow-up of 2.1 years, 26 women in the HRT group and seven in the non-HRT group had a new breast-cancer event. All women with an event in the HRT group and two of those in the non-HRT group were exposed to HRT and most women had their event when on treatment. We decided that these findings indicated an unacceptable risk for women exposed to HRT in the HABITS trial, and the trial was terminated on Dec 17, 2003.
20世纪90年代,斯堪的纳维亚开展了两项随机临床试验,探讨激素替代疗法(HRT)对既往患有乳腺癌的女性是否安全。我们报告了HABITS(乳腺癌后激素替代疗法——是否安全?)安全性分析的结果,这是一项开放随机临床试验,将患者随机分配接受HRT或无激素的最佳治疗。主要终点是任何新发乳腺癌事件。所有分析均按照意向性分析进行。截至2003年9月,434名女性被随机分组;345名至少有一份随访报告。中位随访2.1年后,HRT组有26名女性发生新发乳腺癌事件,非HRT组有7名。HRT组所有发生事件的女性以及非HRT组的2名女性曾接受HRT治疗,且大多数女性在治疗期间发生事件。我们判定这些结果表明在HABITS试验中接受HRT治疗的女性存在不可接受的风险,该试验于2003年12月17日终止。